<yncgh class="rifum"></yncgh>

K8凯发(中国)

Be the most trusted biotech company

2026-05-10

Henlius' Serplulimab Secures EC Approval for Two New Indications, Further Deepening Global Commercialisation Footprint
2026-05-06

Henlius' HLX43 (anti-PD-L1 ADC) Receives PMDA’s Acknowledge to Initiate Global Phase 2/3 Trial in sqNSCLC
2026-04-30

Henlius' Next-Generation Tetra-Specific TCE HLX3901 Doses First Patient in Phase 1 Study, Advancing Multi-Specific Platform into Clinical Validation
2026-04-29

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
2026-04-24

Henlius' 2025 ESG Report
2026-04-24

Henlius' Phase 2/3 Trial of Pimurutamab (HLX07) in Combination with Serplulimab for Advanced sqNSCLC Completes CTN in Australia
2026-04-23

Henlius Presents Four Hanjugator™ ADCs at AACR 2026, with Multiple Potential Best-in-Class Assets Advancing
2026-04-22

Henlius Showcases HLX3902 Preclinical Data at AACR 2026, Highlighting Its CD28-Enabled Multispecific TCE Platform
2026-04-14

NMPA Grants IND Approval for Henlius' Cetuximab Biosimilar HLX05-N

1
...
3
4
5
6
7
8
...
61